Author

John C. Woolcott 1

1 Pfizer Inc,Collegeville,United States

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Alessandro Armuzzi, Christina Ha, Michael Chiorean, Nervin Lawendy, Rajiv Mundayat, Leonardo Salese, John C. Woolcott, Chinyu Su, Iris Dotan

CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE

Alessandro Armuzzi, Nadir Mammar, Benjamin Hoskin, Fritha Hennessy, Puza P. Sharma, Gary Milligan, Ailsa L Hart, Joseph C. Cappelleri, Axel Dignass, John C. Woolcott

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019

Edward V Loftus Jr., Alessandro Armuzzi, Daniel C. Baumgart, Jeffrey R Curtis, Jami A. Kinnucan, Nana Koram, Leonardo Salese, Chinyu Su, Kenneth Kwok, John Woolcott

COMPARATIVE EFFICACY AND SAFETY OF TOFACITINIB AND BIOLOGICS AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

David T. Rubin, Ajibade O Ashaye, Younan Zhang, yingxin xu, Kyle Fahrbach, Lea Ann Chen, Alireza Manuchehri, Cem Kayhan, John Woolcott, Joseph C. Cappelleri

PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME

Mahmoud Mosli, David P. Hudesman, Joana Torres, Leonardo Salese, John C. Woolcott, Rajiv Mundayat, Chinyu Su, Jessica Allegretti

SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Christina Ha, Leonardo Salese, Chinyu Su, Krisztina B Gecse, John Woolcott, Rajiv Mundayat, David P. Hudesman, Jerome Paulissen, Walter Reinisch

Item 1 - 6 / 6
1